Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Xin Zhou und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Pathophysiology, Na…. Hauptthemen laut MEDLINE: ErbB Receptors, Colorectal Neoplasms, Y-Box-Binding Protein 1, Cell Proliferation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
While previous studies have indicated the involvement of Isthmin 1 (ISM1), a secreted protein, in cancer development, the precise mechanisms have remained elusive. In this study, we unveiled that ISM1 is significantly overexpressed in both the blood and tissue samples of colorectal cancer (CRC) patients, correlating with their poor prognosis. Functional experiments demonstrated that enforced ISM1 expression significantly enhances CRC proliferation, migration, invasion and tumor growth. Notably, our investigation reveals an interaction of ISM1 with epidermal growth factor receptor (EGFR), a member of the receptor tyrosine kinase (RTK) family of CRC cells. The binding of ISM1 triggered EGFR activation and initiate downstream signaling pathways. Meanwhile, intracellular ISM1 interacted with Y-box binding protein 1 (YBX1), enhancing its transcriptional regulation on EGFR. Furthermore, our research uncovered the regulation of ISM1 expression by the hypoxia-inducible transcription factor HIF-1α in CRC cells. Mechanistically, we identified HIF-1α as a direct regulator of ISM1, binding to a hypoxia response element on its promoter. This novel mechanism illuminated potential therapeutic targets, offering insights into restraining HIF-1α/ISM1/EGFR-driven CRC progression and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China; Department of Pathophysiology, Nanjing Medical University, Nanjing, 211166, China.
- Department of Pathophysiology, Nanjing Medical University, Nanjing, 211166, China.
- Digestive Endoscopy Department and General Surgery Department, The First Affiliated Hospital of Nanjing Medical University and Jiangsu Province Hospital, Nanjing, 211166, China.
- Department of Pathology, Nanjing Medical University, Nanjing, 211166, China.
- The First School of Clinical Medicine, Nanjing Medical University, Nanjing, Nanjing, 211166, China.
- Department of Plastic Surgery, The Secondary Affiliated Hospital of Nanjing, Medical University, Nanjing, 211166, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Zhou, X., Zhang, K., Wang, C., Teng, Y., Yu, P., Cai, W., Gao, W., Li, M., Ding, Y., Sun, P., Chen, F., Wang, Y., Ma, J., Maeshige, N., Ma, X., Li, Q., Liang, X., Zhang, Y., & Su, D. (2024). Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216868
Vancouver
Zhou X, Zhang K, Wang C, Teng Y, Yu P, Cai W, et al. Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216868
BibTeX
@article{Zhou2024,
author = {Zhou, Xin and Zhang, Kaini and Wang, Chen and Teng, Yunfei and Yu, Peihong and Cai, Wei and Gao, Wenjie and Li, Min and Ding, Ying and Sun, Peng and Chen, Fang and Wang, Yipin and Ma, Juan and Maeshige, Noriaki and Ma, Xiaoqi and Li, Qingguo and Liang, Xiubin and Zhang, Yaqin and Su, Dongming},
title = {Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216868}
}
EUVIMED